| Today's Big NewsNov 2, 2022 |
| By James Waldron The last few weeks have seen GSK and Pfizer locked in a neck-and-neck race to see who can get their respiratory syncytial virus (RSV) to market first. Now, it looks like GSK may have the edge in the U.S., securing priority review status from the FDA and an estimated decision date of May 3. |
|
|
|
By Heather Landi CVS reported a quarterly loss of more than $3 billion to cover its share of a global opioid settlement, but its third-quarter earnings blew past Wall Street estimates. |
By Fraiser Kansteiner Even as it grapples with supply squeezes and the launch of a key competitor’s med, Novo Nordisk isn’t breaking a sweat. |
By Andrea Park Medtronic appears to be circling ever closer to landing the long-awaited FDA clearance for its algorithm-equipped insulin pump—geographically, at least. |
By Kevin Dunleavy Alkermes will separate its oncology sector from its neuroscience business. Underpinning the move is Alkermes’ belief in the blockbuster potential of antipsychotic drug Lybalvi and a likely devaluation of its primary oncology asset, an IL-2 drug, after recent failures by Bristol Myers and Sanofi. |
By Dave Muoio With emergency department and trauma volumes spiking, Grady Health System said it is adding new beds, triage systems and telehealth capabilities to manage demand. The public hospital system is also being supported by local government and providers. |
By Conor Hale AI adopters posted higher diagnosis rates, even if those clinicians had less experience in dealing with complex patients. |
By Annalee Armstrong Metabolic-disorder-focused OrsoBio launched Tuesday with Gilead alums Mani Subramanian, M.D., in the CEO seat and Rob Myers, M.D., serving as chief medical officer. |
By Angus Liu In GSK’s first quarter after the Haleon consumer health spinoff, shingles vaccine Shingrix put up another record show. But while a cloud of Zantac lawsuits gathers over the company, CEO Emma Walmsley is maintaining GSK’s focus on the fundamental business. |
By Frank Diamond Medicare Advantage plans lack competition for market share, says a study by the American Medical Association. |
By Max Bayer Nearly three months after pausing dosing, uniQure's trial in patients with Huntington's disease is set to resume. The trial was paused after three patients treated with the gene therapy were hospitalized. |
By Andrea Park The GlucoContro.online platform allows patients and their caregivers and healthcare providers to dig even deeper into the data collected by Ascensia’s Contour blood glucose monitoring devices. |
Fierce podcasts Don't miss an episode |
| This week on "Podnosis," we talk about a possible national data privacy law and the holes that need to be plugged, particularly in a post-Roe v. Wade world. We also eavesdrop on a panel at the Digital Pharma East conference on opportunities to leverage digital health tools and social determinants data, to improve patients’ health. |
|
|---|
|
|
|
Tuesday, November 8, 2022 | 12:30pm ET / 9:30am PT As a partner in the overall health ecosystem, Myriad Genetics is combining de-identified genetic data with indications, phenotypes, and outcomes to power the next generation of precision medicine advancements. Register now. 
|
|
Webinar Twist Bioscience CSO Dr. Aaron Sato shares how Twist's tools for antibody discovery have been applied to identify antibodies against diverse and challenging targets. See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Presented by: Twist Bioscience |
Whitepaper This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success. Sponsored by: Blue Matter |
Video Revolutionize your monoclonal antibody (mAb) manufacturing process with the Gibco™️ Efficient-Pro™️ Medium and Feed System. Watch our how-to video. Sponsored by: Thermo Fisher Scientific |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored By: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored By: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| |
|
